# CAR-T Cell Therapy Market Report 2026–2035: Size, Share & Trends

> The Global CAR-T Cell Therapy market reached USD 4,372.8 Mn in 2025 and is projected to hit USD 23,915.3 Mn by 2035, an 18.52% CAGR over 2026–2035, according to Vectomat Insights. North America leads with 45.0% share, autologous therapies hold 68.0% of revenue, and Asia Pacific grows fastest as China, Japan and South Korea add approved products and reimbursement.

- Publisher: Vectomat Insights
- Report code: VMI-1-5-20666
- Published: 2026-10-21
- Canonical URL: https://www.vectomatinsights.com/report/car-t-cell-therapy-market
- Base year 2025: USD 4,372.8 Mn
- Forecast 2035: USD 23,915.3 Mn
- CAGR 2026–2035: 18.52%

## Key insights

- The market expands from USD 4,372.8 Mn in 2025 to USD 23,915.3 Mn by 2035, an 18.52% CAGR across the 2026–2035 forecast horizon.
- Autologous CAR-T dominates product type with 68.0% of 2025 revenue (USD 2,973.5 Mn), the format behind all seven FDA-approved CAR-T therapies.
- Allogeneic CAR-T is the fastest-growing product type by a narrow margin, rising from USD 684.8 Mn in 2023 to USD 962.0 Mn in 2025 (an 18.5% two-year CAGR); Allogene's cema-cel passed its ALPHA3 futility analysis in April 2026.
- Non-Hodgkin Lymphoma is the dominant application at 36.0% share (USD 1,574.2 Mn), because large B-cell lymphoma carries the broadest set of CD19 labels across Yescarta, Breyanzi and Kymriah.
- Hospitals & Cancer Centers lead end users with 66.0% share (USD 2,886.0 Mn), since FACT-accredited inpatient capacity still governs where patients are infused; roughly 250 accredited U.S. centers existed by mid-2026.
- North America holds 45.0% of 2025 revenue (USD 1,967.8 Mn), and the United States alone is worth USD 1,574.2 Mn.
- Asia Pacific is the fastest-growing region; South Korea is forecast to grow at 20.7% CAGR and Japan at 18.8% through 2035, both ahead of the U.S. at 17.3%.
- Competition is consolidating around BCMA and in-vivo assets: Gilead closed its USD 7.8 Bn Arcellx acquisition in April 2026, ahead of an FDA decision on anito-cel due 23 December 2026.
- China's June 2026 approval of CARsgen's satri-cel, the first CAR-T cleared for a solid tumor, opens a demand pool that already accounts for 10.0% of 2025 revenue in this report's segmentation.

## Figures

![CAR-T cell therapy market size — USD 4,372.8 Mn (2025) to USD 23,915.3 Mn (2035), 18.52% CAGR | Vectomat Insights](https://www.vectomatinsights.com/assets/img/reports/car-t-cell-therapy-market/car-t-cell-therapy-market-size-vmi.png) — The Global CAR-T Cell Therapy market grows from USD 4,372.8 Mn in 2025 to USD 23,915.3 Mn by 2035, an 18.52% CAGR. Source: Vectomat Insights, CAR-T Cell Therapy Market Report.
![CAR-T cell therapy market drivers, restraints, opportunities and challenges | Vectomat Insights](https://www.vectomatinsights.com/assets/img/reports/car-t-cell-therapy-market/car-t-cell-therapy-market-droc-vmi.png) — Earlier-line approvals, regulatory easing and platform investment drive the market, while cost and center access hold it back. Source: Vectomat Insights, CAR-T Cell Therapy Market Report.
![CAR-T cell therapy market share by region — North America leads with 45.0% in 2025 | Vectomat Insights](https://www.vectomatinsights.com/assets/img/reports/car-t-cell-therapy-market/car-t-cell-therapy-market-regional-share-vmi.png) — North America holds 45.0% of the Global CAR-T Cell Therapy market in 2025, while Asia Pacific grows fastest. Source: Vectomat Insights, CAR-T Cell Therapy Market Report.
![CAR-T cell therapy market segmentation — autologous CAR-T leads with 68.0% share | Vectomat Insights](https://www.vectomatinsights.com/assets/img/reports/car-t-cell-therapy-market/car-t-cell-therapy-market-segments-vmi.png) — Autologous CAR-T, CD19-targeted therapy, non-Hodgkin lymphoma and hospitals & cancer centers lead their dimensions in 2025. Source: Vectomat Insights, CAR-T Cell Therapy Market Report.
![CAR-T cell therapy market share by product type — autologous CAR-T 68.0% in 2025 | Vectomat Insights](https://www.vectomatinsights.com/assets/img/reports/car-t-cell-therapy-market/car-t-cell-therapy-market-product-type-share-vmi.png) — Autologous CAR-T holds 68.0% of the Global CAR-T Cell Therapy market in 2025. Source: Vectomat Insights, CAR-T Cell Therapy Market Report.
![CAR-T cell therapy market share by end user — hospitals & cancer centers 66.0% in 2025 | Vectomat Insights](https://www.vectomatinsights.com/assets/img/reports/car-t-cell-therapy-market/car-t-cell-therapy-market-end-user-share-vmi.png) — Hospitals & Cancer Centers account for 66.0% of the Global CAR-T Cell Therapy market in 2025. Source: Vectomat Insights, CAR-T Cell Therapy Market Report.
![CAR-T cell therapy product type mix by region — North America, Europe, Asia Pacific | Vectomat Insights](https://www.vectomatinsights.com/assets/img/reports/car-t-cell-therapy-market/car-t-cell-therapy-market-regional-segments-vmi.png) — Autologous CAR-T leads the product mix in all three largest regions, with North America showing the highest allogeneic share at 24.0%. Source: Vectomat Insights, CAR-T Cell Therapy Market Report.
![CAR-T cell therapy competitive landscape — 15 companies by commercial scale and platform | Vectomat Insights](https://www.vectomatinsights.com/assets/img/reports/car-t-cell-therapy-market/car-t-cell-therapy-market-competitive-landscape-vmi.png) — Commercial-stage autologous leaders face a growing group of allogeneic, in-vivo and solid-tumor challengers. Source: Vectomat Insights, CAR-T Cell Therapy Market Report.
![CAR-T cell therapy market at a glance — USD 4,372.8 Mn (2025) to USD 23,915.3 Mn, 18.52% CAGR | Vectomat Insights](https://www.vectomatinsights.com/assets/img/reports/car-t-cell-therapy-market/car-t-cell-therapy-market-key-numbers-vmi.png) — Key numbers for the Global CAR-T Cell Therapy market: size, CAGR, leading segments, regions and companies. Source: Vectomat Insights, CAR-T Cell Therapy Market Report.
![United States CAR-T cell therapy market — USD 1,574.2 Mn (2025) to USD 7,763.2 Mn (2035) | Vectomat Insights](https://www.vectomatinsights.com/assets/img/reports/car-t-cell-therapy-market/car-t-cell-therapy-market-united-states-snapshot-vmi.png) — The U.S. CAR-T Cell Therapy market grows from USD 1,574.2 Mn in 2025 to USD 7,763.2 Mn by 2035 at a 17.3% CAGR. Source: Vectomat Insights, CAR-T Cell Therapy Market Report.
![Germany CAR-T cell therapy market — USD 354.2 Mn (2025) to USD 1,688.1 Mn (2035) | Vectomat Insights](https://www.vectomatinsights.com/assets/img/reports/car-t-cell-therapy-market/car-t-cell-therapy-market-germany-snapshot-vmi.png) — Germany's CAR-T Cell Therapy market grows from USD 354.2 Mn in 2025 to USD 1,688.1 Mn by 2035 at a 16.9% CAGR. Source: Vectomat Insights, CAR-T Cell Therapy Market Report.
![South Korea CAR-T cell therapy market — USD 149.5 Mn (2025) to USD 981.1 Mn (2035) | Vectomat Insights](https://www.vectomatinsights.com/assets/img/reports/car-t-cell-therapy-market/car-t-cell-therapy-market-south-korea-snapshot-vmi.png) — South Korea's CAR-T Cell Therapy market grows from USD 149.5 Mn in 2025 to USD 981.1 Mn by 2035 at a 20.7% CAGR, the fastest of any tracked country. Source: Vectomat Insights, CAR-T Cell Therapy Market Report.

## Market size (USD million)

| Year | Value |
|---|---|
| 2023 | 3,112.9 |
| 2024 | 3,689.6 |
| 2025 | 4,372.8 |
| 2026 | 5,182.6 |
| 2027 | 6,142.5 |
| 2028 | 7,280.1 |
| 2029 | 8,628.3 |
| 2030 | 10,226.3 |
| 2031 | 12,120.2 |
| 2032 | 14,364.9 |
| 2033 | 17,025.2 |
| 2034 | 20,178.3 |
| 2035 | 23,915.3 |

## Share by Product Type (2025)

| Segment | Share | USD Mn |
|---|---|---|
| Autologous CAR-T | 68.0% | 2,973.5 |
| Allogeneic CAR-T | 22.0% | 962.0 |
| In-Vivo CAR-T | 10.0% | 437.3 |

## Share by Target Antigen (2025)

| Segment | Share | USD Mn |
|---|---|---|
| CD19-Targeted | 50.0% | 2,186.4 |
| BCMA-Targeted | 28.0% | 1,224.4 |
| CD22-Targeted | 10.0% | 437.3 |
| Others | 12.0% | 524.7 |

## Share by Application (2025)

| Segment | Share | USD Mn |
|---|---|---|
| Non-Hodgkin Lymphoma | 36.0% | 1,574.2 |
| Acute Lymphoblastic Leukemia | 24.0% | 1,049.5 |
| Multiple Myeloma | 22.0% | 962.0 |
| Solid Tumors | 10.0% | 437.3 |
| Others | 8.0% | 349.8 |

## Share by End User (2025)

| Segment | Share | USD Mn |
|---|---|---|
| Hospitals & Cancer Centers | 66.0% | 2,886.0 |
| Specialty Treatment Centers | 22.0% | 962.0 |
| Academic & Research Institutes | 12.0% | 524.7 |

## Regional share

| Region | Share | USD Mn |
|---|---|---|
| North America | 45.0% | 1,967.8 |
| Europe | 27.0% | 1,180.7 |
| Asia Pacific | 19.0% | 830.8 |
| Latin America | 4.0% | 174.9 |
| The Middle East | 3.0% | 131.2 |
| Africa | 2.0% | 87.5 |

## Key companies

- Gilead Sciences (U.S.): CD19 CAR-T via Kite (Yescarta, Tecartus); BCMA via anito-cel
- Novartis (Switzerland): Kymriah (CD19) and rapidly manufactured rap-cel for autoimmune disease
- Bristol Myers Squibb (U.S.): Breyanzi (CD19) and Abecma (BCMA)
- Johnson & Johnson (U.S.): Carvykti (BCMA) co-commercialized with Legend Biotech
- Legend Biotech (U.S.): Carvykti (cilta-cel) manufacturing and commercialization partner
- Autolus Therapeutics (U.K.): Aucatzyl (obe-cel), CD19 CAR-T for adult B-ALL
- JW Therapeutics (China): Carteyva (relma-cel), CD19 CAR-T in China
- CARsgen Therapeutics (China): Satri-cel (Claudin18.2) and zevor-cel (BCMA)
- IASO Biotherapeutics (China): Fucaso (eque-cel, BCMA) and in-vivo CAR-T
- Allogene Therapeutics (U.S.): Allogeneic CD19 CAR-T cema-cel
- Caribou Biosciences (U.S.): CRISPR-edited allogeneic CAR-T (vispa-cel, CB-011)
- AbbVie (U.S.): In-vivo CD19 CAR-T (CPTX2309) for autoimmune disease
- AstraZeneca (U.K.): In-vivo lentiviral ENaBL platform via EsoBiotec
- ImmunoACT (India): NexCAR19 (talicabtagene autoleucel), low-cost CD19 CAR-T
- Miltenyi Biomedicine (Germany): CliniMACS Prodigy point-of-care manufacturing and zamto-cel (CD20/CD19)

## FAQs

### What does the VMI CAR-T Cell Therapy report include?

The report covers market size from 2023 to 2025 and forecasts through 2035 across four segmentation dimensions: Product Type, Target Antigen, Application and End User. It includes six regional analyses in which Middle East and Africa are separate regions, 35+ country breakdowns, a Production & Volume analysis, drivers, restraints, opportunities and challenges, and profiles of 15 companies, in 300+ pages from Vectomat Insights.

### What is the CAR-T Cell Therapy market size and forecast?

Vectomat Insights values the Global CAR-T Cell Therapy market at USD 4,372.8 Mn in 2025 and forecasts USD 23,915.3 Mn by 2035, an 18.52% CAGR across 2026–2035. Autologous products generate 68.0% of base-year revenue, while allogeneic and in-vivo platforms together hold 32.0% and carry most of the long-term upside as manufacturing models change, according to the VMI CAR-T Cell Therapy Market report.

### How is the CAR-T Cell Therapy market segmented in this report?

Four dimensions are covered, each with 2023–2025 revenue tables and 2035 forecasts. Product Type splits autologous, allogeneic and in-vivo CAR-T. Target Antigen splits CD19, BCMA, CD22 and other targets such as Claudin18.2. Application covers non-Hodgkin lymphoma, acute lymphoblastic leukemia, multiple myeloma, solid tumors and others. End User covers hospitals and cancer centers, specialty treatment centers and academic and research institutes, per Vectomat Insights.

### Which countries are covered in this report?

The report covers 35+ countries across six regions: North America (U.S., Canada, Mexico), Europe (including Germany, France, U.K., Italy and Spain), Asia Pacific (including China, Japan, India, South Korea and Australia), Latin America (including Brazil and Argentina), the Middle East (GCC, Israel, Turkey, Iran) and Africa (including South Africa and Egypt). Middle East and Africa are separate regions in this analysis, according to Vectomat Insights.

### What customization options are available?

Buyers can request up to 20% free customization. Typical requests include extra country breakdowns, additional company profiles, splits by line of therapy or manufacturing model, and pricing and reimbursement tables for specific markets. Customization is scoped before purchase, so the delivered report matches your decision. Custom scopes beyond that allowance are quoted separately. Contact sales@vectomatinsights.com with your requirements and a Vectomat Insights analyst will confirm scope and delivery timing.

### How can I access or purchase the CAR-T Cell Therapy report?

Visit www.vectomatinsights.com to request a free sample, view the table of contents or buy the full CAR-T Cell Therapy Market report. A sample shows the report's structure and data depth before you commit. Single-user, multi-user and enterprise licenses are available, with delivery as a PDF by email and through the online download portal. For corporate licensing or bulk purchases, email sales@vectomatinsights.com, and the Vectomat Insights team will respond with options.

### What research methodology does VMI use for this report?

Vectomat Insights combines a bottom-up model of treated patients and realized prices with a top-down check against reported sales of approved CAR-T products. Inputs include regulatory approval records, company filings, CMS payment rules, health technology assessments from G-BA and NICE, and clinical data from major congresses. Segment and regional figures are triangulated against the VMI Data Tracker, according to Vectomat Insights.

Cite as: Vectomat Insights (2026). CAR-T Cell Therapy Market Report. https://www.vectomatinsights.com/report/car-t-cell-therapy-market